INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--()--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Recro Pharma, Inc. (''Recro Pharma” or ''the Company'') (NASDAQ: REPH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's shares between July 31, 2017, and May 23, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before July 30, 2018.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, Recro Pharma made false and misleading statements to the marketplace. The Company’s lead product, IV meloxicam, was unlikely to receive FDA approval due to lacking sufficient supporting clinical data to demonstrate significant clinical benefits. As a result, Recro Pharma’s public statements were materially false and misleading throughout the class period and did not accurately reflect the results of business operations and the financial health of the Company. According to the lawsuit, when accurate information about the Company became apparent in the market, investors suffered damages.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

Release Summary

INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc.

Contacts

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com